Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AgfiledCriticalJagotec Ag
Priority to CO04066265ApriorityCriticalpatent/CO5590935A2/en
Publication of CO5590935A2publicationCriticalpatent/CO5590935A2/en
1.- Una formulación farmacéutica en forma coloidal para aplicación tópica para la terapia y profilaxis de cambios patológicos de la piel y/o estructuras integumentarias de la piel y/o membranas mucosas, que incluyen membranas mucosas del tubo digestivo, vías urogenitales y sistema bronquial y/o conjuntiva, que contiene:(a) una fase lipofílica en una cantidad de 1 - 10% en peso;(b) una mezcla de surfactante y co-surfactante en una cantidad de 1 - 50% en peso;(c) una fase hidrofílica en una cantidad de 40 - 80% en peso y(d) como ingrediente activo, ciclosporina y/o derivados de la misma en una concentración de 0.1 - 20% en peso.2.- La formulación farmacéutica de conformidad con la reivindicación 1, caracterizada porque la fase lipofílica es seleccionada a partir de aceites, ceras ó grasas farmacéuticas.1.- A pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and / or integumentary structures of the skin and / or mucous membranes, which include mucous membranes of the digestive tract, urogenital pathways and bronchial system and / or conjunctiva, which contains: (a) a lipophilic phase in an amount of 1-10% by weight; (b) a mixture of surfactant and co-surfactant in an amount of 1-50% by weight; (c) a hydrophilic phase in an amount of 40-80% by weight and (d) as active ingredient, cyclosporine and / or derivatives thereof in a concentration of 0.1-20% by weight.2.- The pharmaceutical formulation in accordance with the claim 1, characterized in that the lipophilic phase is selected from oils, waxes or pharmaceutical fats.
CO04066265A2004-07-132004-07-13
PHARMACEUTICAL FORMULATION THAT INCLUDE CYCLOSPORINE AND USE OF THE SAME
CO5590935A2
(en)
Pharmaceutical formulation comprising mixture of anti-alpha4beta7 antibody, a buffering agent, and citrate; use of said formulation to treat inflammatory bowel disease.
Use of an aqueous pharmaceutical formulation comprising 0.5-10% of terbinafine or a salt thereof, 2-10% of a phospholipid and 1-5% of a surfactant, to prepare a medicament useful for treating a fungal infection; pharmaceutical formulation
Derivatives of 2,3-dihydroimidazo [1,2-c] quinazoline substituted with amino alcohols that are useful for treating hyperproliferative disorders and diseases associated with angiogenesis
Topical pharmaceutical composition comprising nanoporous, spherical calcium phosphate particles, where at least 90% or more of the particles have an average diameter of 2 microns or less and are bound to a pharmacologically active agent.
PHARMACEUTICAL COMPOSITION THAT INCLUDES A CHITOSAN, A COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENT, AND A VOLATILE SOLVENT; AND ITS USE TO TREAT PSORIASIS, MICOSIS BETWEEN OTHER DISEASES.
A NEW PHARMACEUTICALLY ACCEPTABLE SALT OF 2-HIDROXI-3- (5- (MORFOLIN-4-ILMETIL) -PIRIDIN-2-L) 1H-INDOL-5-CARBONITRILE, PROCEDURES FOR THE PREPARATION, COMPOSITIONS CONTAINING IT AND APPLICATIONS
Pharmaceutical composition comprising at least one internal non-lipoid phase and at least one external lipoid phase that is bioadhesive to a surface of the vaginal mucosa and comprising danazol of 1 to 30% by weight; preparation procedure; administration system; and use to treat inflammatory conditions